載入...
Tocilizumab in COVID‐19 interstitial pneumonia
BACKGROUND: Published reports on tocilizumab in COVID‐19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open‐label trial, structured according to Simon's optimal design, aims to identify factors predicting which patient...
Na minha lista:
| 發表在: | J Intern Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8013903/ https://ncbi.nlm.nih.gov/pubmed/33511686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13231 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|